Biosite and Oxford Genome Sciences Announce Collaboration in Colorectal Cancer
News Apr 04, 2006
Biosite® Incorporated and privately-held Oxford Genome Sciences (UK) Ltd. (OGeS) have announced a collaboration for the evaluation of protein-based disease markers for colorectal cancer.
The markers could be used for the development of potential blood-based diagnostic products aimed at expanding personalized therapeutic options for colorectal cancer.
In particular, these blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate therapeutic option.
Today, the fecal occult blood test and colonoscopy, a highly invasive procedure, are the most frequently used screening and diagnostic methods for colorectal cancer, which has a 30 to 40 percent recurrence rate within an average of 18 months after primary diagnosis.
OGeS has developed a database (the Oxford Genome Anatomy Project or OGAP(R)) that integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases.
Under the terms of the collaboration, OGeS will identify at least 25 proteins discovered in blood and tissue samples from relapsing colorectal cancer patients and Biosite will have the rights to develop blood-based diagnostic tests using one or more of those biomarkers.
"We are increasingly interested in studying selected areas of cancer that can benefit from rapid, effective, non-invasive diagnostic technologies," said Kim Blickenstaff, Biosite's chairman and chief executive officer.
"This collaboration expands our research aimed at evaluation of diagnostic tools for relapsing colorectal cancer by providing us with access to high quality validation of potentially valuable protein biomarkers."
"Relapsing disease is the major cause of suffering and death in colorectal cancer patients and there is a complete lack of clinical tools to aid physicians in the process of deciding whom to treat when and whether to treat with chemotherapy," said Christian Rohlff, OGeS' chief executive officer.
"This collaboration with Biosite underpins our corporate objective of applying new strategies to the emerging field of personalized medicine in oncology to improve patient outcomes."
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.